The therapeutic effect of Gansu tablet combined with entecavir on severe hepatitis B patients and its influence on their immune function
10.3969/j.issn.1006-2483.2021.04.032
- VernacularTitle:肝苏片联合恩替卡韦对重症乙肝患者治疗效果及对患者免疫功能的影响
- Author:
Aihua GAO
1
;
Xinli WANG
1
;
Yanqin SUN
2
;
Qinghe JIANG
1
;
Xia LIU
3
Author Information
1. Hepatology Department, Cangzhou Infectious Disease Hospital, Cangzhou , Hebei 061001, China
2. Outpatient Department, Cangzhou Infectious Disease Hospital, Cangzhou , Hebei 061001, China
3. Tuberculosis Department, Cangzhou Infectious Disease Hospital, Cangzhou , Hebei 061001, China
- Publication Type:Journal Article
- Keywords:
Gansu tablet;
Entecavir;
Severe hepatitis B;
Immunological function
- From:
Journal of Public Health and Preventive Medicine
2021;32(2):133-136
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the therapeutic effect of Gansu tablets combined with entecavir on patients with severe hepatitis B and the effect on patients’ immune function. Methods A total of 108 cases of severe hepatitis B patients who were treated in our hospital from January 2018 to January 2019 were randomly divided into two groups: entecavir group and combination treatment group, 54 cases each. Entecavir group was treated with entecavir, and combination treatment group was treated with Gansu tablets and entecavir. The levels of AST, GGT, alt, FIB, APTT, Pt, GSH Px, LPO and MDA in serum were measured by enzyme-linked immunosorbent assay. T-lymphocyte subsets were measured by cell analyzer. The therapeutic effect and adverse reactions were compared between the two groups. Results The levels of AST, GGT and ALT in the combined treatment group were significantly lower than those in the entecavir group (P < 0.05). After treatment, the FIB level of patients in the combined treatment group was higher than that in the entecavir group, and the APTT and Pt levels were lower than those in the entecavir group (P<0.05). After treatment, the GSH PX level of the combined treatment group was higher than that of entecavir group, and the LPO and MDA levels were lower than that of entecavir group (P<0.05). After treatment, the level of CD8 + was lower than that of entecavir group, and the level of CD4 + and CD3 + was higher than that of entecavir group (P<0.05). The total effective rate of the combined treatment group was higher than that of the entecavir group (P < 0.05). The incidence of adverse reactions in the combined treatment group was slightly higher than that in the entecavir group, but the difference was not statistically significant (P>0.05). Conclusion The use of Gansu tablets combined with entecavir in the treatment of severe hepatitis B patients was able to improve liver function, improve coagulation function, reduce oxidative stress injury, and improve the immune function of patients, demonstrating a potential clinical application value.
